Sucraid® Is an Effective Treatment for CSID
Three clinical trials have evaluated the therapeutic benefits of sacrosidase (the generic name for Sucraid®).
In This Section
The first study was designed to determine the ability of a replacement enzyme for sucrase to improve the gastrointestinal (GI) symptoms of study participants diagnosed with Congenital Sucrase-Isomaltase Deficiency (CSID).
The therapeutic benefit of the replacement enzyme was measured by the hydrogen breath test, which measures the activity of the sucrase enzyme (see the breath tests). This study also measured the ability of four different doses of the replacement enzyme sacrosidase to relieve GI symptoms associated with CSID. The study included 28 patients with confirmed CSID. In CSID patients up to 3 years of age, 86% had complete relief from their symptoms. In patients over 3 years of age, 77% had complete relief of their symptoms. The study showed that sacrosidase was effective at relieving GI symptoms in patients with CSID and was most effective at the highest doses.1
In the second clinical trial, the researchers also used the hydrogen breath test to measure the ability of sacrosidase, taken by the study participants diagnosed with CSID.
The relief of GI symptoms was also measured after treatment with four different doses of sacrosidase. The researchers concluded that sacrosidase is an effective and well-tolerated treatment for sucrase deficiency associated with CSID. Patients showed a marked decrease in the hydrogen breath test results when they received sacrosidase in comparison to placebo indicating that the sacrosidase was working to help digest sucrose.2
The third clinical trial was conducted over a period of several years in 32 participants diagnosed with CSID and treated with Sucraid®.
The researchers again found therapy with Sucraid® to be well-tolerated and effective in reducing the GI symptoms of sucrase deficiency associated with CSID. Study participants in this long-term study spanned a broad range of ages. While taking Sucraid®, the study participants consumed a normal, sucrose-containing diet and experienced fewer GI symptoms than before therapy with Sucraid®.3
- Treem WR, Ahsan N, Sullivan B, et al. Evaluation of liquid yeast-derived sucrase enzyme replacement in patients with sucrase-isomaltase deficiency. Gastroenterology. 1993;105(4):1061-1068.
- Treem WR, McAdams L, Stanford L, Kastoff G, Justinich C, Hyams J. Sacrosidase therapy for Congenital Sucrase-Isomaltase Deficiency. J Pediatr Gastroenterol Nutr. 1999;28(2):137-142.
- QOL Medical, LLC. Open-label, long-term study of sucrase enzyme therapy for Congenital Sucrase-Isomaltase Deficiency. Data on file, OMC-SUC-3. 1997.